Enochian Biosciences Inc (OTCMKTS:ENOB) Director Henrik Gronfeldt-Sorensen purchased 50,000 shares of the firm’s stock in a transaction on Thursday, January 10th. The shares were acquired at an average price of $2.00 per share, for a total transaction of $100,000.00. The acquisition was disclosed in a filing with the SEC, which is available through this link.
Shares of OTCMKTS ENOB opened at $9.25 on Monday. Enochian Biosciences Inc has a 52-week low of $3.32 and a 52-week high of $9.50.
TRADEMARK VIOLATION WARNING: This piece was published by WKRB News and is the sole property of of WKRB News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.wkrb13.com/2019/01/14/insider-buying-enochian-biosciences-inc-enob-director-purchases-100000-00-in-stock.html.
Enochian Biosciences Inc, a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients.
Further Reading: What is Compound Interest?
Receive News & Ratings for Enochian Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enochian Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.